Abstract
Clinical genetic testing identifies variants causal for hereditary cancer, information that is used for risk assessment and clinical management. Unfortunately, some variants identified are of uncertain clinical significance (VUS), complicating patient management. Case-control data is one evidence type used to classify VUS, and previous findings indicate that case-control likelihood ratios (LRs) outperform odds ratios for variant classification. As an initiative of the Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Analytical Working Group we analyzed germline sequencing data of BRCA1 and BRCA2 from 96,691 female breast cancer cases and 303,925 unaffected controls from three studies: the BRIDGES study of the Breast Cancer Association Consortium, the Cancer Risk Estimates Related to Susceptibility consortium, and the UK Biobank. We observed 11,227 BRCA1 and BRCA2 variants, with 6,921 being coding, covering 23.4% of BRCA1 and BRCA2 VUS in ClinVar and 19.2% of ClinVar curated (likely) benign or pathogenic variants. Case-control LR evidence was highly consistent with ClinVar assertions for (likely) benign or pathogenic variants; exhibiting 99.1% sensitivity and 95.4% specificity for BRCA1 and 92.2% sensitivity and 86.6% specificity for BRCA2. This approach provides case-control evidence for 785 unclassified variants, that can serve as a valuable element for clinical classification.
Competing Interest Statement
The following authors declare conflicts not directly relevant to this work as stated below. VK-MT and GDE have received consultancies from AstaZeneca and Everything Genetic Ltd. ACA and DFE are named creators of the BOADICEA model which has been licensed by Cambridge Enterprise (University of Cambridge). SJH has received speaker fees from AstraZeneca and Pfizer Ltd. SY has received research funding from AstraZeneca and Repare Therapeutics and participates in the advisory board for AstraZeneca. JWW has received consulting fees from Natera, MyOme, Cancer IQ, equity from Natera and speaker fees from AstraZeneca. All the other authors declare no conflict of interest.
Funding Statement
This research has been conducted using the UK Biobank Resource under application number 102655. Access to the UK Biobank data has been funded by an internal research grant of the Cyprus Institute of Neurology and Genetics.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research received approval by the Cyprus National Bioethics Committee (EEBK EΠ 2020.01.224). All the studies were approved by the relevant ethics review boards and used appropriate consent procedures.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Individual level data for the BCAC data are not publicly available due to ethical review board constraints but are available on request through the BCAC Data Access Co-ordinating Committee (BCAC{at}medschl.cam.ac.uk). Requests for access to UK Biobank data should be made to the UK Biobank Access Management Team (access{at}ukbiobank.ac.uk). According to the "UK Biobank best practice approaches on the publication of small numbers, Tables and/or results of any UK Biobank data there should have a minimum number of 5 reported participants within a cell". Therefore, for variants present in less than 5 individuals, carrier count (Carriers, N) was replaced by "<5".
